Please assess the completion status of the following clinical trial:

Trial Title: Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females of non childbearing potential;~* Patients with T2DM, inadequately controlled with metformin;~* HbA1c ≥7.0% to ≤10.5% (for T2DM); HbA1c \<6.5% (for non-diabetic obese, if enrolled)~* Total body weight \>50 kg (110 lbs)~* BMI ≥24.5 to ≤45.5 kg/m2 (T2DM), BMI \>30.5 to ≤45.5 kg/m2 (for non-diabetic obese)~Exclusion Criteria~* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, hepatic, psychiatric, neurological, dermatological, or allergic disease;~* Medical history of T2DM (for non-diabetic obese participants, if enrolled);~* Diagnosis of type 1 diabetes mellitus or secondary forms of diabetes;~* Evidence or history of clinically significant cardiovascular disease;~* Any malignancy not considered cured;~* Acute pancreatitis or history of chronic pancreatitis;~* Acute gallbladder disease;~* Any condition possibly affecting drug absorption;~* Personal or family history of MTC or MEN2;~* Medical or psychiatric condition that may increase the risk of study participation;~* Any vaccination within the 1 week prior to admission to the CRU;~* Previous administration with an investigational drug within 30 days or 5 half-lives preceding first dose;~* Known prior participation in a trial involving PF-07081532;~* A positive urine drug screen at screening or admission;~* Positive testing at screening for HIV, HBsAg, HBcAb, HBsAb or HCVAb;~* Positive COVID-19 test at screening or admission;~* Supine BP ≥160 mm Hg (systolic) or ≥100 mm Hg (diastolic);~* 12-lead ECG clinically relevant abnormalities that may affect participant safety or interpretation of study results;~* Participants with ANY of the following abnormalities in clinical laboratory tests: \*AST or ALT level ≥1.5x ULN;~  * Total bilirubin level ≥1.5x ULN;~ * TSH\> ULN;~ * Fasting C-peptide \<0.8 ng/mL;~ * Serum calcitonin \> ULN;~ * Amylase \> ULN;~ * Lipase \> ULN;~ * eGFR \<60 mL/min/1.73m2 (per MDRD equation);~ * FPG \>270 mg/dL~* History of alcohol abuse, binge drinking and/or any illicit drug use or dependence within 6 months of Screening;~* Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing;~* History of sensitivity to heparin or heparin induced thrombocytopenia;~* Known intolerance to any GLP-1R agonist.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- PF-07081532 (Type: EXPERIMENTAL): multiple dosing, once-daily for 42 days
- Placebo (Type: PLACEBO_COMPARATOR): multiple dosing, once-daily for 42 days

Based on this trial design, predict the completion outcome and termination type (if applicable).